Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 40, 31, 3, 2, 19, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 9 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Nasopharyngeal Cancer – Overview
Nasopharyngeal Cancer – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Nasopharyngeal Cancer – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasopharyngeal Cancer – Companies Involved in Therapeutics Development
ADC Therapeutics SA
Advenchen Laboratories LLC
Akeso Inc
Alphamab Oncology
Ambrx Biopharma Inc
Amgen Inc
Apollomics Inc
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
AVEO Pharmaceuticals Inc
BeiGene Ltd
Biomics Biotechnologies Co Ltd
BioSyngen Pte Ltd
BP InnoMed Ltd
Bristol-Myers Squibb Co
Chengdu Wonho Biology Engineering Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China Immunotech Co Ltd
Compugen Ltd
Eli Lilly and Co
EpimAb Biotherapeutics Inc
Eutilex Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Geneius Biotechnology Inc
GenFleet Therapeutics (Shanghai) Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
GeoVax Labs Inc
GlaxoSmithKline Plc
Guangzhou Bairui Biomedical Technology Co Ltd
Guangzhou Doublle Bioproduct Inc
Harbin Gloria Pharmaceuticals Co Ltd
HRYZ (ShenZhen) Biotech Co
Huabo Biopharm (Shanghai) Co Ltd
Immix BioPharma Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunomic Therapeutics Inc
Incyte Corp
Inhibrx Inc
Inmune Bio Inc
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Joint Biosciences Ltd
Karyopharm Therapeutics Inc
Kuur Therapeutics Ltd
Lion TCR Pte Ltd
Merck & Co Inc
Merck KGaA
Molecular Targeting Technologies Inc
Neonc Technologies Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Oxford Vacmedix UK Ltd
Polaris Pharmaceuticals Inc
Qilu Puget Sound Biotherapeutics Corp
Rapa Therapeutics LLC
RAPT Therapeutics Inc
Rubius Therapeutics Inc
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shenghe (China) Biopharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Soricimed Biopharma Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
TCR Cure Biopharma Technology Co Ltd
Tessa Therapeutics Ltd
TOT Biopharm Co Ltd
Transcenta Holding Ltd
Vectorite Biomedical Inc
Viracta Therapeutics Inc
Xencor Inc
Xiangxue Life Sciences
Y-Biologics Inc
Nasopharyngeal Cancer – Drug Profiles
(curcumin + doxorubicin) – Drug Profile
anlotinib hydrochloride – Drug Profile
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer – Drug Profile
apatinib mesylate – Drug Profile
APG-1387 – Drug Profile
APL-502 – Drug Profile
ARX-305 – Drug Profile
ASTX-660 – Drug Profile
ATA-190 – Drug Profile
atezolizumab – Drug Profile
avelumab – Drug Profile
baltaleucel-T – Drug Profile
bavunalimab – Drug Profile
BDB-001 – Drug Profile
bevacizumab – Drug Profile
BG-001 – Drug Profile
BG-002 – Drug Profile
BGB-10188 – Drug Profile
bintrafusp alfa – Drug Profile
BMS-986207 – Drug Profile
Cabometyx – Drug Profile
cadonilimab – Drug Profile
camrelizumab – Drug Profile
Cellular Immunotherapy for EBV Associated Malignancies – Drug Profile
Cellular Immunotherapy for Epstein–Barr Virus Infections and Nasopharyngeal Cancer – Drug Profile
Cellular Immunotherapy for Nasopharyngeal Cancer – Drug Profile
Cellular Immunotherapy for Oncology – Drug Profile
Cellular Immunotherapy to Target CD137L for Nasopharyngeal Cancer – Drug Profile
COM-701 – Drug Profile
dalpiciclib – Drug Profile
DC-120 – Drug Profile
DKY-709 – Drug Profile
DN-1508052 – Drug Profile
donafenib tosylate – Drug Profile
durvalumab – Drug Profile
durvalumab + tremelimumab – Drug Profile
E-10B – Drug Profile
EBViNT – Drug Profile
EDS-01 – Drug Profile
eltanexor – Drug Profile
EMB-02 – Drug Profile
EMB-09 – Drug Profile
epacadostat – Drug Profile
ficlatuzumab – Drug Profile
FLX-475 – Drug Profile
GB-3015 – Drug Profile
GB-5008 – Drug Profile
gedeptin – Drug Profile
Gene Therapy for Epstein–Barr Virus Associated Nasopharyngeal Cancer – Drug Profile
Gene Therapy for Nasopharyngeal Cancer – Drug Profile
Gene Therapy for Oncology – Drug Profile
Gene Therapy to Target EPCAM for Oncology – Drug Profile
Gene Therapy to Target FAP for Nasopharyngeal Cancer and Solid Tumor – Drug Profile
Gene Therapy to Target Latent Membrane Protein-2 for Epstein-Barr Virus Associated Cancer – Drug Profile
Gene Therapy to Target LMP1 for Epstein-Barr Virus Associated Nasopharyngeal Cancer – Drug Profile
Gene Therapy to Target LMP2 for EBV Associated Nasopharyngeal Carcinoma – Drug Profile
Gene Therapy to Target LMP2 for Nasopharyngeal Carcinoma – Drug Profile
Gene Therapy To Target Nectin4 and NKG2DL for Nasopharyngeal Cancer and Solid Tumor – Drug Profile
geptanolimab – Drug Profile
GF-101 – Drug Profile
GNSTEBV-001 – Drug Profile
GR-1405 – Drug Profile
HB-0021 – Drug Profile
IBC-0966 – Drug Profile
IBI-310 – Drug Profile
IBI-323 – Drug Profile
IMM-01 – Drug Profile
INBRX-106 – Drug Profile
INKmune – Drug Profile
ipilimumab + nivolumab – Drug Profile
ITI-4000 – Drug Profile
izuralimab – Drug Profile
JS-003 – Drug Profile
JS-004 – Drug Profile
KLA-167 – Drug Profile
KN-046 – Drug Profile
L-100s – Drug Profile
L-200s – Drug Profile
L-300s – Drug Profile
lucitanib – Drug Profile
LY-3434172 – Drug Profile
MAK-683 – Drug Profile
MASCT – Drug Profile
mipasetamab uzoptirine – Drug Profile
Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma – Drug Profile
Monoclonal Antibody to Target BARF-1 for Epstein-Barr Virus Infections and Oncology – Drug Profile
MRG-003 – Drug Profile
MVA vaccine – Drug Profile
nanatinostat – Drug Profile
NEO-212 – Drug Profile
nimotuzumab biosimilar – Drug Profile
niraparib – Drug Profile
nivolumab – Drug Profile
NJH-395 – Drug Profile
OVM-400 – Drug Profile
OVV-01 – Drug Profile
pegargiminase – Drug Profile
pembrolizumab – Drug Profile
penpulimab – Drug Profile
Peptide to Inhibit EBNA1 And LMP1 for Nasopharyngeal Cancer – Drug Profile
PSB-205 – Drug Profile
RAPA-201 – Drug Profile
rovaleucel – Drug Profile
RTX-321 – Drug Profile
SHR-1701 – Drug Profile
SIM-325 – Drug Profile
sintilimab – Drug Profile
Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer – Drug Profile
SORC-13 – Drug Profile
spartalizumab – Drug Profile
Synthetic Peptide to Target Somatostatin Receptor for Oncology – Drug Profile
tabelecleucel – Drug Profile
TAEST-16007 – Drug Profile
tipifarnib – Drug Profile
tislelizumab – Drug Profile
toripalimab – Drug Profile
TQB-2858 – Drug Profile
TST-005 – Drug Profile
TT-11X – Drug Profile
Vaccine for EBV Associated Nasopharyngeal Cancer and Hodgkin Lymphoma – Drug Profile
VK-2019 – Drug Profile
vudalimab – Drug Profile
Xgeva – Drug Profile
YBL-006 – Drug Profile
YTE-001 – Drug Profile
zimberelimab – Drug Profile
Nasopharyngeal Cancer – Dormant Projects
Nasopharyngeal Cancer – Discontinued Products
Nasopharyngeal Cancer – Product Development Milestones
Featured News & Press Releases
Apr 19, 2022: BeiGene presents updated results from phase 3 RATIONALE-309 Trial of PD-1 inhibitor Tislelizumab in first-line RM-NPC in Virtual ASCO Plenary Series
Apr 08, 2022: Junshi Biosciences and Coherus present results of phase 3 study of toripalimab in first line treatment of recurrent or metastatic nasopharyngeal carcinoma at 2022 AACR Annual Meeting
Mar 07, 2022: Voluntary announcement – JS001sc injection received the clinical trial approval
Dec 10, 2021: BeiGene presents results from phase 3 trial of Tislelizumab in nasopharyngeal cancer at ESMO Immuno-Oncology Congress 2021
Dec 03, 2021: Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List
Dec 02, 2021: BeiGene to present new clinical data on Tislelizumab at ESMO IO Congress 2021
Nov 29, 2021: Junshi Biosciences announces approval of supplemental new drug application by NMPA for Toripalimab in combination with Cisplatin and Gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma
Nov 20, 2021: Sichuan Kelun Pharmaceutical Co : Announcement on the acceptance of the listing application for PD-L1 new drug Tetlizumab injection by NMPA
Nov 01, 2021: Coherus and Junshi Biosciences announce FDA acceptance of BLA filing for toripalimab for treatment of nasopharyngeal carcinoma
Oct 31, 2021: Shanghai Junshi Bioscience Co: Voluntary announcement –the FDA accepted biologics license application of Toripalimab for treatment of nasopharyngeal carcinoma
Oct 06, 2021: Viracta Therapeutics initiates phase 1b/2 trial in Epstein-Barr Virus-Positive (EBV+) solid tumors
Sep 20, 2021: Pembrolizumab does not prolong overall survival compared to chemotherapy in platinum-pretreated recurrent or metastatic nasopharyngeal carcinoma
Sep 15, 2021: Coherus and Junshi Biosciences announce results from phase 3 study of toripalimab published in September Issue of Nature Medicine
Sep 01, 2021: Coherus and Junshi Biosciences announce completion of rolling BLA submission to U.S. FDA for toripalimab for the treatment of nasopharyngeal carcinoma
Aug 22, 2021: BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in nasopharyngeal cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Nasopharyngeal Cancer, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Universities/Institutes, 2022
Table 7: Products under Development by Companies, 2022
Table 8: Products under Development by Companies, 2022 (Contd..1)
Table 9: Products under Development by Companies, 2022 (Contd..2)
Table 10: Products under Development by Companies, 2022 (Contd..3)
Table 11: Products under Development by Companies, 2022 (Contd..4)
Table 12: Products under Development by Companies, 2022 (Contd..5)
Table 13: Products under Development by Companies, 2022 (Contd..6)
Table 14: Products under Development by Universities/Institutes, 2022
Table 15: Number of Products by Stage and Target, 2022
Table 16: Number of Products by Stage and Target, 2022 (Contd..1)
Table 17: Number of Products by Stage and Target, 2022 (Contd..2)
Table 18: Number of Products by Stage and Target, 2022 (Contd..3)
Table 19: Number of Products by Stage and Mechanism of Action, 2022
Table 20: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 21: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Table 22: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
Table 23: Number of Products by Stage and Route of Administration, 2022
Table 24: Number of Products by Stage and Molecule Type, 2022
Table 25: Nasopharyngeal Cancer – Pipeline by ADC Therapeutics SA, 2022
Table 26: Nasopharyngeal Cancer – Pipeline by Advenchen Laboratories LLC, 2022
Table 27: Nasopharyngeal Cancer – Pipeline by Akeso Inc, 2022
Table 28: Nasopharyngeal Cancer – Pipeline by Alphamab Oncology, 2022
Table 29: Nasopharyngeal Cancer – Pipeline by Ambrx Biopharma Inc, 2022
Table 30: Nasopharyngeal Cancer – Pipeline by Amgen Inc, 2022
Table 31: Nasopharyngeal Cancer – Pipeline by Apollomics Inc, 2022
Table 32: Nasopharyngeal Cancer – Pipeline by Ascentage Pharma Group International, 2022
Table 33: Nasopharyngeal Cancer – Pipeline by Astex Pharmaceuticals Inc, 2022
Table 34: Nasopharyngeal Cancer – Pipeline by AstraZeneca Plc, 2022
Table 35: Nasopharyngeal Cancer – Pipeline by Atara Biotherapeutics Inc, 2022
Table 36: Nasopharyngeal Cancer – Pipeline by AVEO Pharmaceuticals Inc, 2022
Table 37: Nasopharyngeal Cancer – Pipeline by BeiGene Ltd, 2022
Table 38: Nasopharyngeal Cancer – Pipeline by Biomics Biotechnologies Co Ltd, 2022
Table 39: Nasopharyngeal Cancer – Pipeline by BioSyngen Pte Ltd, 2022
Table 40: Nasopharyngeal Cancer – Pipeline by BP InnoMed Ltd, 2022
Table 41: Nasopharyngeal Cancer – Pipeline by Bristol-Myers Squibb Co, 2022
Table 42: Nasopharyngeal Cancer – Pipeline by Chengdu Wonho Biology Engineering Co Ltd, 2022
Table 43: Nasopharyngeal Cancer – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Table 44: Nasopharyngeal Cancer – Pipeline by China Immunotech Co Ltd, 2022
Table 45: Nasopharyngeal Cancer – Pipeline by Compugen Ltd, 2022
Table 46: Nasopharyngeal Cancer – Pipeline by Eli Lilly and Co, 2022
Table 47: Nasopharyngeal Cancer – Pipeline by EpimAb Biotherapeutics Inc, 2022
Table 48: Nasopharyngeal Cancer – Pipeline by Eutilex Co Ltd, 2022
Table 49: Nasopharyngeal Cancer – Pipeline by Exelixis Inc, 2022
Table 50: Nasopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 51: Nasopharyngeal Cancer – Pipeline by Geneius Biotechnology Inc, 2022
Table 52: Nasopharyngeal Cancer – Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2022
Table 53: Nasopharyngeal Cancer – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
Table 54: Nasopharyngeal Cancer – Pipeline by GeoVax Labs Inc, 2022
Table 55: Nasopharyngeal Cancer – Pipeline by GlaxoSmithKline Plc, 2022
Table 56: Nasopharyngeal Cancer – Pipeline by Guangzhou Bairui Biomedical Technology Co Ltd, 2022
Table 57: Nasopharyngeal Cancer – Pipeline by Guangzhou Doublle Bioproduct Inc, 2022
Table 58: Nasopharyngeal Cancer – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
Table 59: Nasopharyngeal Cancer – Pipeline by HRYZ (ShenZhen) Biotech Co, 2022
Table 60: Nasopharyngeal Cancer – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
Table 61: Nasopharyngeal Cancer – Pipeline by Immix BioPharma Inc, 2022
Table 62: Nasopharyngeal Cancer – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
Table 63: Nasopharyngeal Cancer – Pipeline by Immunomic Therapeutics Inc, 2022
Table 64: Nasopharyngeal Cancer – Pipeline by Incyte Corp, 2022
Table 65: Nasopharyngeal Cancer – Pipeline by Inhibrx Inc, 2022
Table 66: Nasopharyngeal Cancer – Pipeline by Inmune Bio Inc, 2022
Table 67: Nasopharyngeal Cancer – Pipeline by Innovent Biologics Inc, 2022
Table 68: Nasopharyngeal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Table 69: Nasopharyngeal Cancer – Pipeline by Johnson & Johnson, 2022
Table 70: Nasopharyngeal Cancer – Pipeline by Joint Biosciences Ltd, 2022
Table 71: Nasopharyngeal Cancer – Pipeline by Karyopharm Therapeutics Inc, 2022
Table 72: Nasopharyngeal Cancer – Pipeline by Kuur Therapeutics Ltd, 2022
Table 73: Nasopharyngeal Cancer – Pipeline by Lion TCR Pte Ltd, 2022
Table 74: Nasopharyngeal Cancer – Pipeline by Merck & Co Inc, 2022
Table 75: Nasopharyngeal Cancer – Pipeline by Merck KGaA, 2022
Table 76: Nasopharyngeal Cancer – Pipeline by Molecular Targeting Technologies Inc, 2022
Table 77: Nasopharyngeal Cancer – Pipeline by Neonc Technologies Inc, 2022
Table 78: Nasopharyngeal Cancer – Pipeline by Novartis AG, 2022
Table 79: Nasopharyngeal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Table 80: Nasopharyngeal Cancer – Pipeline by Oxford Vacmedix UK Ltd, 2022
Table 81: Nasopharyngeal Cancer – Pipeline by Polaris Pharmaceuticals Inc, 2022
Table 82: Nasopharyngeal Cancer – Pipeline by Qilu Puget Sound Biotherapeutics Corp, 2022
Table 83: Nasopharyngeal Cancer – Pipeline by Rapa Therapeutics LLC, 2022
Table 84: Nasopharyngeal Cancer – Pipeline by RAPT Therapeutics Inc, 2022
Table 85: Nasopharyngeal Cancer – Pipeline by Rubius Therapeutics Inc, 2022
Table 86: Nasopharyngeal Cancer – Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022
Table 87: Nasopharyngeal Cancer – Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Table 88: Nasopharyngeal Cancer – Pipeline by Shanghai GeneChem Co Ltd, 2022
Table 89: Nasopharyngeal Cancer – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Table 90: Nasopharyngeal Cancer – Pipeline by Shanghai Miracogen Inc, 2022
Table 91: Nasopharyngeal Cancer – Pipeline by Shenghe (China) Biopharmaceutical Co Ltd, 2022
Table 92: Nasopharyngeal Cancer – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Table 93: Nasopharyngeal Cancer – Pipeline by Soricimed Biopharma Inc, 2022
Table 94: Nasopharyngeal Cancer – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Table 95: Nasopharyngeal Cancer – Pipeline by TCR Cure Biopharma Technology Co Ltd, 2022
Table 96: Nasopharyngeal Cancer – Pipeline by Tessa Therapeutics Ltd, 2022
Table 97: Nasopharyngeal Cancer – Pipeline by TOT Biopharm Co Ltd, 2022
Table 98: Nasopharyngeal Cancer – Pipeline by Transcenta Holding Ltd, 2022
Table 99: Nasopharyngeal Cancer – Pipeline by Vectorite Biomedical Inc, 2022
Table 100: Nasopharyngeal Cancer – Pipeline by Viracta Therapeutics Inc, 2022
Table 101: Nasopharyngeal Cancer – Pipeline by Xencor Inc, 2022
Table 102: Nasopharyngeal Cancer – Pipeline by Xiangxue Life Sciences, 2022
Table 103: Nasopharyngeal Cancer – Pipeline by Y-Biologics Inc, 2022
Table 104: Nasopharyngeal Cancer – Dormant Projects, 2022
Table 105: Nasopharyngeal Cancer – Dormant Projects, 2022 (Contd..1)
Table 106: Nasopharyngeal Cancer – Dormant Projects, 2022 (Contd..2)
Table 107: Nasopharyngeal Cancer – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Nasopharyngeal Cancer, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings